The approval in the second-line EGFR- and MET-altered setting was based on results from the SACHI trial, which compared Orpathys and Tagrisso against chemo.

The company is developing treatments for autism and substance use disorders tailored to patient subgroups identified by clinico-genomic signatures.

UCLA-led investigators say additional research is needed into why guideline-recommended genetic testing remains low among ...

The agency will allow BMS to discontinue REMS programs for both therapies and reduce certain patient monitoring requirements.

The firm will take a different reimbursement strategy for the test than its prior owner Biocept, which stopped selling it after filing for bankruptcy in 2023.

A legislative ban on pharma ads, a tool for companies to amplify messaging on drugs, including for precision medicines, is sure to face legal challenges, experts say.

The company said the therapy is the first allogenic therapy developed with its Tmod technology to be tested in humans.

NEW YORK – Allarity Therapeutics has begun dosing patients in a Phase II trial studying its dual PARP and WNT pathway inhibitor stenoparib in patients with advanced, recurrent, platinum-resistant or ...